EFG Asset Management North America Corp. Has $6.89 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

EFG Asset Management North America Corp. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 21,162 shares of the biopharmaceutical company’s stock after selling 3,529 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 1.0% of EFG Asset Management North America Corp.’s holdings, making the stock its 13th largest holding. EFG Asset Management North America Corp.’s holdings in Alnylam Pharmaceuticals were worth $6,893,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the period. Adage Capital Partners GP L.L.C. increased its holdings in Alnylam Pharmaceuticals by 203.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company’s stock worth $76,195,000 after purchasing an additional 189,128 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after purchasing an additional 185,783 shares in the last quarter. SCS Capital Management LLC bought a new position in Alnylam Pharmaceuticals during the 1st quarter worth about $46,194,000. Finally, Orbis Allan Gray Ltd raised its position in Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock valued at $441,462,000 after buying an additional 162,121 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares of the company’s stock, valued at $397,724.38. This represents a 97.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Colleen F. Reitan sold 18,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares of the company’s stock, valued at approximately $362,390. The trade was a 95.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 98,144 shares of company stock worth $44,160,261 in the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $423.47 on Wednesday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The stock has a market capitalization of $55.51 billion, a PE ratio of -171.45 and a beta of 0.36. The firm has a 50 day moving average of $459.45 and a 200-day moving average of $373.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $943.37 million. During the same quarter in the previous year, the firm earned ($0.50) EPS. Alnylam Pharmaceuticals’s revenue was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ALNY. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Piper Sandler restated an “overweight” rating and issued a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Bank of America raised their price target on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Finally, Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Monday, October 6th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $478.67.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.